Table 3. Analysis of genotype frequencies of NOS2 gene polymorphisms, based on low and high PSA level, in subjects with BPH.
| SNP (locus) | Genotype | PSA level (ng mL−1) |
Model | OR (95% CI) | P-value | |
|---|---|---|---|---|---|---|
| < 1.5 |
≥ 1.5 |
|||||
| n = 84 (%) | n = 144 (%) | |||||
| rs2779248 | T/T | 70 (83.3) | 111 (77.1) | Codominant | 1.26 (0.71–2.24) | 0.430 |
| Promoter | T/C | 11 (13.1) | 29 (20.1) | Dominant | 1.50 (0.74–3.01) | 0.250 |
| −278 | C/C | 3 (3.6) | 4 (2.8) | Recessive | 0.71 (0.15–3.33) | 0.670 |
| rs10459953 | G/G | 23 (27.4) | 43 (29.9) | Codominant | 0.98 (0.68–1.44) | 0.940 |
| 5′UTR | C/G | 42 (50.0) | 66 (45.8) | Dominant | 0.88 (0.48–1.62) | 0.680 |
| C/C | 19 (22.6) | 35 (24.3) | Recessive | 1.10 (0.58–2.10) | 0.760 | |
| rs2297518 | G/G | 63 (75.0) | 104 (72.2) | Codominant | 1.19 (0.68–2.08) | 0.540 |
| Missense | A/G | 20 (23.8) | 36 (25.0) | Dominant | 1.16 (0.63–2.17) | 0.630 |
| Ser608Leu | A/A | 1 (1.2) | 4 (2.8) | Recessive | 2.05 (0.22–18.92) | 0.500 |
Abbreviations: 5′UTR, 5′-untranslated region; BPH, benign prostatic hyperplasia; CI, confidence interval; n, number of subjects; NOS2, nitric oxide synthase 2; OR, odds ratio; PSA, prostate-specific antigen; SNP, single nucleotide polymorphism.
Note: P-values were obtained from logistic regression analyses with the codominant, dominant and recessive models without Bonferroni correction.